Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 7/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3961464 | 0.82 | KCNA5 (0.42) | TACR1TSHRBCHEACHE | |
| SCHEMBL3961467 | 0.82 | KCNA5 (0.42) | TACR1TSHRBCHEACHE | |
| SCHEMBL3961461 | 0.82 | KCNA5 (0.42) | TACR1TSHRBCHEACHE | |
| SCHEMBL19333763 | 0.82 | KCNA5 (0.42) | TACR1TSHRBCHEACHE | |
| SCHEMBL3961462 | 0.82 | KCNA5 (0.42) | TACR1TSHRBCHEACHE | |
| Hydrochloric Acid SCHEMBL6234960 | 0.81 | TSHR (0.41) | TACR1TSHRBCHEACHE | |
| SCHEMBL311161 | 0.79 | MAOB (0.44) | — | |
| SCHEMBL840905 | 0.79 | MAOB (0.44) | — | |
| SCHEMBL841243 | 0.79 | MAOB (0.44) | — | |
| SCHEMBL19333652 | 0.79 | TACR1 (0.43) | TACR1CTSLBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693072-B2 | Elastase inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-02-17 | — | — | US | disclosed |
| EP-0804465-B1 | NOVEL ELASTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2003-08-06 | — | — | EP | disclosed |
| US-20030096759-A1 | Novel elastase inhibitors | AVENTISUB II INC. | 2003-05-22 | — | — | US | disclosed |
| EP-0804465-A1 | NOVEL ELASTASE INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1995033763-A1 | NOVEL ELASTASE INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1995-12-14 | — | — | WO | disclosed |
| US-4082736-A | NOVEL IMMUNOLOGICAL ADJUVANT COMPOUNDS AND METHODS OF PREPARATION THEREOF | SYNTEX (U.S.A.) INC. (US) | 1978-04-04 | — | — | US | disclosed |
| US-4082735-A | NOVEL IMMUNOLOGICAL ADJUVANT COMPOUNDS AND METHODS OF PREPARATION THEREOF | SYNTEX (U.S.A.) INC. (US) | 1978-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096759-A1 | Novel elastase inhibitors | ELANE, SERPINB1, MMP8 | KLK7 1230/4885KLK5 962/4885TACR1 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.